Have a personal or library account? Click to login
Retrospective Study of the Use of Heparins in Pregnant Women and in vitro Testing on the HCT 116 Colorectal Carcinoma Cell Line Cover

Retrospective Study of the Use of Heparins in Pregnant Women and in vitro Testing on the HCT 116 Colorectal Carcinoma Cell Line

Open Access
|Jan 2024

Figures & Tables

Fig. 1.

Age distribution of the subjects
Age distribution of the subjects

Fig. 2.

Rural/urban area distribution of subjects
Rural/urban area distribution of subjects

Fig. 3.

In vitro HCT 116 cell evaluation after 72 h of incubation with HEP and FRAX (10, 25, 50, and 100 UI) by performing the MTT assay. The data are presented as viability % normalized to untreated cells (expressed as average values ± SD of three independent experiments). One-way ANOVA analysis and the Dunett’s multiple comparisons post-test were conducted to identify the statistical differences between obtained data (* p < 0.1).
In vitro HCT 116 cell evaluation after 72 h of incubation with HEP and FRAX (10, 25, 50, and 100 UI) by performing the MTT assay. The data are presented as viability % normalized to untreated cells (expressed as average values ± SD of three independent experiments). One-way ANOVA analysis and the Dunett’s multiple comparisons post-test were conducted to identify the statistical differences between obtained data (* p < 0.1).

Fig. 4.

Images showing the confluence and morphological aspect of HCT 116 colorectal carcinoma cells after 72 h of treatment with HEP and FRAX at 10, 25, 50 and 100 UI. The scale bars represent 50 µm.
Images showing the confluence and morphological aspect of HCT 116 colorectal carcinoma cells after 72 h of treatment with HEP and FRAX at 10, 25, 50 and 100 UI. The scale bars represent 50 µm.

Fig. 5.

A) Pictures illustrating the migratory capacity of HCT 116 cells after treatment with HEP 100UI and FRAX 100UI for 24h. The scale bars represent 50 µm. B) Graphic depiction of the migratory potential of HCT 116 cells after the treatment with HEP 100UI and FRAX 100UI. The bar graphs are exposed as % of wound closure after 24 hours compared to the initial distance at t0. The results are expressed as averages ± SD of 3 independent experiments. One-way ANOVA analysis and the Dunett’s multiple comparisons post-test were applied to follow the statistical differences between obtained results (**** p < 0.0001).
A) Pictures illustrating the migratory capacity of HCT 116 cells after treatment with HEP 100UI and FRAX 100UI for 24h. The scale bars represent 50 µm. B) Graphic depiction of the migratory potential of HCT 116 cells after the treatment with HEP 100UI and FRAX 100UI. The bar graphs are exposed as % of wound closure after 24 hours compared to the initial distance at t0. The results are expressed as averages ± SD of 3 independent experiments. One-way ANOVA analysis and the Dunett’s multiple comparisons post-test were applied to follow the statistical differences between obtained results (**** p < 0.0001).

Fig. 6.

Pictures of the HCT 116 cellular nuclei counterstained with Hoechst 33342 reagent after 72 h of treatment with HEP and FRAX 10 and 100UI. The yellow arrows assign nuclei with apoptotic signs. The scale bars represent 100 µm.
Pictures of the HCT 116 cellular nuclei counterstained with Hoechst 33342 reagent after 72 h of treatment with HEP and FRAX 10 and 100UI. The yellow arrows assign nuclei with apoptotic signs. The scale bars represent 100 µm.

Diagnostic and laboratory analyzes according to the discharge ticket

Patients (n)Patients (% of total)
Discharge diagnosisCare given to the mother for the uterine scar due to a previous surgery1741.46
Medical induction of labor failure614.63
Birth by caesarean section24.88
Other diagnosis*1536.59

Hemoglobin valueUnder 12 g/dL37.32
Over 16 g/dL3278.05

Hematocrit valueUnder 35 %1331.71
Over 46%00.00

Coagulation/fibrinogen valueUnder 200 mg/dL00.00
Over 400 mg/dL41100.00

Characteristics of subjects according to their discharge note

DiagnosticLMWHep treatmentThe type of birthApgar indexAborted/dead


Pregnancy < 36 weeksPregnancy > 36 weeksNC0–78–10
Patients (n)15734132431765.008
Patients (% of total)16.3079.3544.5734.7846.7418.4870.6516.30
DOI: https://doi.org/10.2478/jccm-2024-0009 | Journal eISSN: 2393-1817 | Journal ISSN: 2393-1809
Language: English
Page range: 73 - 84
Submitted on: Oct 27, 2023
Accepted on: Jan 8, 2024
Published on: Jan 30, 2024
Published by: University of Medicine, Pharmacy, Science and Technology of Targu Mures
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2024 Felicia Fiat, Diana-Aurora Arnautu, Brenda Cristina Bernad, Alina Anton, Iasmina Marcovici, Alexandra-Denisa Semenescu, Elena Silvia Bernad, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution 4.0 License.